Evidence Intelligence Platform

Decision intelligence for precision medicine.

ELOYA connects biomedical evidence, omics data, knowledge graphs, and governed AI workflows to support target discovery, biomarker strategy, and translational oncology decisions.

Evidence-grounded AIGoverned workflowsPrecision oncology intelligence

Request a private enterprise demo Open product screens

app.eloya.com / evidence-explorer / KRAS-G12C-NSCLC

TL Translational Lead

1,284Evidence records

46Clinical trials

312Publications

18Biomarker notes

98%Traceability

Evidence Explorer Graph Reviewer QueueExports

Prioritized evidence tableUpdated 2026-06-18 · 10:42 UTC

Entity	Finding	Source	Confidence	Reviewer	Timestamp
KRAS G12C	Actionable mutation context in NSCLC	PMID35658005	High	Signed · Oncology	10:42 UTC
Adagrasib	Therapeutic evidence linked to G12C	NCT03785249	High	Signed · Clinical	10:38 UTC
Sotorasib	Comparator evidence for KRAS G12C	NCT03600883	Med-high	Pending · Translational	10:33 UTC
MAPK pathway	Mechanism and resistance context	Pathway DB	Medium	Queued	10:29 UTC
NSCLC cohort	Patient-selection evidence summary	Internal memo	Needs review	Open	10:21 UTC

Showing 1–5 of 1,284 evidence records

Knowledge graphKRAS module · 9 linked nodes

KRASG12CNSCLCAdagrasibSotorasibMAPK

Reviewer statusDecision Review · v0.9

Clinical reviewer: signed evidence interpretation.

Oncology reviewer: signed biomarker rationale.

Translational reviewer: pending comparator review.

Model log attachedLineage completeExport locked

Audit trailPart 11-ready pattern

Evidence snapshot: 2026-06-18
Knowledge graph version: KG-KRAS-024
Prompt version: RAG-KG-014
Decision memo: awaiting final sign-off

Built for

Enterprise biomedical teams.

▦Pharma

◇Biotech

◎Diagnostics

✚Academic Medicine

App screenshots

Product screens generated from the implemented app pages.

These frames point to the included app pages and can be replaced with real exported screenshots after backend implementation.

Evidence Explorer — prioritized evidence records, filters, counts, reviewers, timestamps.

Knowledge Graph — KRAS G12C disease, pathway, trial, and drug relationships.

Reviewer Console — reviewer status, decision memo, audit export readiness.

Scientific workflow

Evidence sources become traceable decision intelligence.

Evidence SourcesPubMed, ClinicalTrials, COSMIC, cBioPortal, internal docs, omics pipelines.

NormalizationEntities, synonyms, cohorts, trial identifiers, assay context, and source metadata.

Knowledge GraphTargets, variants, diseases, drugs, pathways, publications, trials, and mechanisms.

ReasoningEvidence-grounded synthesis, contradiction flags, confidence scoring, and rationale draft.

Human ReviewReviewer gates, sign-off, versioning, model logs, and audit-ready controls.

Decision MemoSource-linked output for biomarker strategy, portfolio review, and executive decisions.

Early Access Program

Pilot Program Alpha: KRAS G12C evidence review.

Program structure for first enterprise pilots, replacing the earlier illustrative-only case study.

Goals

Validate evidence coverage, reviewer workflow usability, lineage completeness, and decision memo quality for a KRAS G12C translational oncology workflow.

Outcomes

Target outcomes: ↓45% evidence review time, 100% decision traceability, >90% reviewer agreement, 100% audit completeness.

Metrics

Evidence coverage, contradiction detection, reviewer acceptance, lineage completeness, audit export readiness, and executive usability.

Leadership and advisors

Authority layer for scientific and enterprise trust.

Founder

Dr. Nabil Atallah — Biomedical AI, multi-omics, cloud/HPC, responsible AI, translational informatics, and regulated workflow design.

Scientific Advisory Board

— Translational Oncology
— Biomarker Strategy
— Enterprise Validation Advisors
— GxP / Validation
— Clinical Development

Business value and validation

Pilot targets, ROI levers, and scientific validation framework.

Use target values until production pilots produce validated customer results.

↓45%Target evidence review time

100%Decision traceability target

>90%Reviewer agreement target

100%Audit completeness target

Metric	Goal	Enterprise meaning
Evidence Coverage	95%	Key public/internal evidence represented in the pilot workspace.
Traceability	100%	Every decision statement links back to evidence or reviewer rationale.
Reviewer Agreement	>90%	Scientific reviewers agree with evidence classification and decision framing.
Audit Completeness	100%	Model logs, dataset versions, timestamps, and reviewer events are captured.

Why ELOYA

Built beyond search and generic LLM answers.

Traditional Search	Generic LLM	ELOYA
PubMed-only evidence discovery	Can hallucinate or miss source constraints	Evidence-grounded biomedical intelligence
No governance layer	No reliable lineage by default	Full traceability and reviewer controls
Manual synthesis burden	Generic answers without scientific workflow context	Biomedical reasoning tied to targets, biomarkers, trials, and decisions
Hard to defend decisions	Hard to reproduce outputs	Exportable decision memo with audit trail

Regulated science

Governance language for enterprise biomedical environments.

HIPAA21 CFR Part 11GxPEU AI ActNIST AI RMFSOC2 roadmap

Private enterprise demo

See how ELOYA turns biomedical evidence into governed discovery intelligence.

Request a private demo for KRAS G12C pilot workflows, precision oncology decision support, and enterprise validation controls.

Before launch, connect this form to HubSpot, Salesforce, Formspree, Netlify Forms, or a secure backend endpoint. Current static package uses a placeholder endpoint.

*Scale figures and pilot outcome values are design targets until validated through production deployments and documented customer pilots.